tert-butyl (2-mercaptoadamantan-2-yl)acetate | 260268-02-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (2-mercaptoadamantan-2-yl)acetate
• 英文别名: tert-butyl 2-(2-sulfanyladamantan-2-yl)acetate；tert-Butyl-2-(2-sulfanyladamant-2-yl)acetate；tert-butyl 2-(2-sulfanyl-2-adamantyl)acetate
• CAS: 260268-02-8
• 化学式: C₁₆H₂₆O₂S
• 分子量: 282.447
• InChiKey: VVCTVZAGEKZCFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  27.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (2-mercaptoadamantan-2-yl)acetate 在 Lithium aluminium hydride 、 乙酸乙酯 、 ice 、 二氯甲烷 、 Brine 、 Sodium sulfate-III 作用下， 以 二氯甲烷 为溶剂， 反应 1.08h， 以to give the title compound (3.1 g), mp 68-70° C.的产率得到2-(2-Sulfanyladamantan-2-yl)ethan-1-ol
  参考文献：
  名称：

  Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use

  摘要：

  本发明描述了新型的硝酸化和/或亚硝酸化α-肾上腺素受体拮抗剂，以及包含至少一种硝酸化和/或亚硝酸化α-肾上腺素受体拮抗剂的新型组合物，可选地，还包括一种或多种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物，和/或一种或多种血管活性剂。本发明还提供了包含至少一种α-肾上腺素受体拮抗剂、一种或多种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或一种或多种血管活性剂的新型组合物。本发明还提供了治疗或预防男性和女性性功能障碍、增强男性和女性性反应、治疗或预防良性前列腺增生、高血压、充血性心力衰竭、变异性（Printzmetal）心绞痛、青光眼、神经退行性疾病、血管痉挛性疾病、认知障碍、急迫性尿失禁或过度活动膀胱，并逆转麻醉状态的方法。

  公开号：

  US20020143007A1
• 作为产物：
  描述：

  金刚烷-2-硫酮 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 环己烷 为溶剂， 反应 2.67h， 以93%的产率得到tert-butyl (2-mercaptoadamantan-2-yl)acetate
  参考文献：
  名称：

  Nitrostated and nitrosylated prostaglandins, compositions and methods of use

  摘要：

  本发明描述了新型亚硝酸化和/或亚硝基化前列腺素，以及包含至少一种亚硝酸化和/或亚硝基化前列腺素的新型组合物，可选择地还包括至少一种捐赠、转移或释放一氧化氮、提高内源性内皮源性舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物，和/或至少一种血管活性药物。本发明还提供了包含至少一种前列腺素和至少一种S-亚硝基硫醇化合物的新型组合物，可选择地还包括至少一种血管活性药物。前列腺素最好是前列腺素E1化合物，更好的是前列腺素E1的异前列腺素，S-亚硝基硫醇化合物最好是S-亚硝基谷胱甘肽。本发明还提供了治疗或预防男性和女性性功能障碍、增强男性和女性性反应以及治疗或预防脑血管疾病、心血管疾病、良性前列腺增生（BPH）、青光眼、消化性溃疡或引发流产的方法。本发明的化合物和/或组合物也可以以药物配套的形式提供。

  公开号：

  US07176238B1

文献信息

• Nitrosated and nitrosylated &agr;-adrenergic receptor antagonist, compositions and methods of use
  申请人：NitroMed, Inc.

  公开号：US06469065B1

  公开（公告）日：2002-10-22

  The present invention describes novel nitrosated and/or nitrosylated &agr;-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated &agr;-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one &agr;-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.

  本发明描述了新型的硝化和/或亚硝化α-肾上腺素受体拮抗剂，以及含有至少一种硝化和/或亚硝化α-肾上腺素受体拮抗剂的新型组合物，可选地，含有一种或多种捐赠、转移或释放一氧化氮、提高内源性内皮衍生舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物，和/或一种或多种血管活性剂。本发明还提供了含有至少一种α-肾上腺素受体拮抗剂和一种或多种捐赠、转移或释放一氧化氮、提高内源性内皮衍生舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或一种或多种血管活性剂的新型组合物。本发明还提供了治疗或预防男性和女性性功能障碍、增强男性和女性性反应、治疗或预防良性前列腺增生、高血压、充血性心力衰竭、变异（Printzmetal）心绞痛、青光眼、神经退行性疾病、血管痉挛性疾病、认知障碍、急迫性尿失禁或过度活跃膀胱，并逆转麻醉状态的方法。
• Nitric oxide donors, compositions and methods of use related applications
  申请人：——

  公开号：US20030203915A1

  公开（公告）日：2003-10-30

  The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering the nitric oxide donor optionally in combination with at least one therapeutic agent. The invention also provides methods for treating inflammation, pain, fever, gastrointestinal disorders, respiratory disorders and sexual dysfunctions. The nitric oxide donors donate, transfer or release nitric oxide, and/or elevate endogenous levels of endothelium-derived relaxing factor, and/or stimulate endogenous synthesis of nitric oxide and/or are substrates for nitric oxide synthase and are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The therapeutic agent can optionally be substituted with at least one NO and/or NO 2 group (i.e., nitrosylated and/or nitrosated). The invention also provides novel compositions and kits comprising at least one nitric oxide donor and/or at least one therapeutic agent.

  该发明描述了新颖的一氧化氮供体和至少含有一个一氧化氮供体的新型组合物。该发明还提供了至少含有一个一氧化氮供体的新型组合物，以及可选地至少含有一个治疗剂。该发明的化合物和组合物也可以与基质结合。该发明还提供了治疗心血管疾病的方法，用于抑制血液暴露于医疗器械引起的血小板聚集和血小板粘附，用于治疗由于异常细胞增殖导致的病理状况；移植排斥、自身免疫、炎症、增殖、过度增殖、血管疾病；用于减少瘢痕组织或抑制伤口收缩，特别是通过给予一氧化氮供体的预防性和/或治疗性治疗以及至少一个治疗剂的组合来治疗再狭窄的方法。该发明还提供了治疗炎症、疼痛、发热、胃肠道疾病、呼吸道疾病和性功能障碍的方法。一氧化氮供体可以捐赠、转移或释放一氧化氮，并/或提高内源性内皮血管舒张因子的水平，并/或刺激内源性一氧化氮的合成和/或是一氧化氮合酶的底物，能够在生理条件下释放一氧化氮或间接地将一氧化氮传递或转移至靶向部位。治疗剂可以选择性地用至少一个NO和/或NO2基（即亚硝基化和/或亚硝化）替代。该发明还提供了至少含有一个一氧化氮供体和/或至少一个治疗剂的新型组合物和试剂盒。
• Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
  申请人：NitroMed, Inc.

  公开号：US20040266828A1

  公开（公告）日：2004-12-30

  The present invention describes novel nitrosated and/or nitrosylated proton pump inhibitor compounds, and novel compositions comprising at least one proton pump inhibitor compound that is optionally substituted with at least one NO and/or NO 2 group, and, optionally, at least one compound that donates, transfers, or releases nitric oxide, induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one nonsteroidal antiinflammatory drug, selective COX-2 inhibitor, antacid, bismuth-containing reagent, acid-degradable antibacterial compound, and mixtures thereof. The present invention also provides methods for treating and/or preventing gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti- Helicobacter pylon properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating Helicobacter pylori and viral infections. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.

  本发明描述了新型的硝化和/或亚硝化质子泵抑制剂化合物，以及包含至少一种质子泵抑制剂化合物的新型组合物，该化合物可以选择地取代至少一个NO和/或NO2基团，并且可以选择地包含至少一种提供、转移或释放一氧化氮、诱导内源性一氧化氮或内皮源性舒张因子产生、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物，和/或至少一种非甾体抗炎药、选择性COX-2抑制剂、抗酸剂、含铋试剂、酸降解抗菌化合物及其混合物。本发明还提供了治疗和/或预防胃肠道疾病的方法；促进溃疡愈合；减少溃疡复发；改善质子泵抑制剂的胃保护性能、抗幽门螺杆菌性能或抗酸性能；减少或降低与非甾体抗炎化合物使用相关的胃肠道毒性；治疗幽门螺杆菌和病毒感染。本发明的化合物和/或组合物还可以以药用工具包的形式提供。
• Preparation of functionalized tertiary thiols and nitrosothiols
  作者：Chia-En Lin、Stewart K. Richardson、Weiheng Wang、Tiansheng Wang、David S. Garvey

  DOI：10.1016/j.tet.2006.06.019

  日期：2006.8

  The development and preparation of five series of tertiary thiols and nitrosothiols as nitric oxide releasing molecules functionalized with acid, alcohol, or amine groups for future conjugation are reported.

  据报道，开发并制备了五系列叔硫醇和亚硝基硫醇，它们是一氧化氮释放分子，可被酸，醇或胺基官能化，以用于将来的缀合。
• H2 RECEPTOR ANTAGONIST COMPOUNDS IN COMBINATION WITH NITRIC OXIDE DONORS, COMPOSTIONS AND METHODS OF USE
  申请人：——

  公开号：US20020077343A1

  公开（公告）日：2002-06-20

  The present invention describes novel nitrosated and/or nitrosylated H 2 receptor antagonist compounds, and novel compositions comprising at least one H 2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO 2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase. The present invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H 2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.

  本发明描述了新型的硝化和/或亚硝化H2受体拮抗剂化合物，以及包含至少一种H2受体拮抗剂化合物的新型组合物，该化合物可以选择性地取代至少一个NO和/或NO2基团，并且可以选择性地包含至少一种捐赠、转移或释放一氧化氮的化合物，刺激内源性一氧化氮合成，提高内源性内皮源性松弛因子水平或是一氧化氮合酶的底物。本发明还描述了治疗和/或预防胃肠道疾病的方法；改善H2受体拮抗剂的胃保护性能；减少溃疡的复发；促进溃疡愈合；预防和/或治疗炎症和微生物感染、眼科疾病和障碍、多发性硬化症和病毒感染；减少或降低非甾体抗炎化合物使用所带来的胃肠道毒性。